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Trypanosoma cruzia b s t r a c t
CYP51 (sterol 14a-demethylase) is an efﬁcient target for clinical and agricultural antifungals and an
emerging target for treatment of Chagas disease, the infection that is caused by multiple strains of a
protozoan pathogen Trypanosoma cruzi. Here, we analyze CYP51A from the Y strain T. cruzi. In this
protein, proline 355, a residue highly conserved across the CYP51 family, is replaced with serine. The
puriﬁed enzyme retains its catalytic activity, yet has been found less susceptible to inhibition. These
biochemical data are consistent with cellular experiments, both in insect and human stages of the
pathogen. Comparative structural analysis of CYP51 complexes with VNI and two derivatives sug-
gests that broad-spectrum CYP51 inhibitors are likely to be preferable as antichagasic drug
candidates.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction dazole and nifurtimox. Both drugs are highly toxic, cause severeTrypanosoma cruzi is a protozoan parasite that uses blood-suck-
ing triatomine insects (kissing bugs) as vectors and a variety of
mammals as hosts. In mammals, the pathogen multiplies intracel-
lularly, populating different organs and tissues, though damaging
predominantly the heart or/and gastrointestinal tract [1]. T. cruzi
was ﬁrst reported as the causative agent of human infections by
Carlos Chagas in 1909 [2], but since then both the disease and
the pathogen have remained remarkably neglected. Current thera-
peutic options are limited mainly to two nitroderivatives, benzni-side effects, and their efﬁciency in the chronic phase is still debated
[1]. Chagas disease remains endemic in Latin America [3] and is
now becoming an emerging global health problem, mainly due to
human/vector migration. For example, it has been reported that
only in the USA there is up to one million infected [4], of them
more than 260000 patients living in Texas alone [5]. Spreading
the disease all over the world eventually attracted attention, and
two antifungal drugs, inhibitors of fungal sterol 14a-demethylase
(CYP51), posaconazole and ravuconazole, that demonstrated
promising results in animal models of Chagas disease [6–8] have
been advanced into clinical trials [9]. The results, however, appear
to be controversial (80% treatment failure [10]), thus calling for
better, safer, and cost-efﬁcient rationally designed T. cruzi CYP51
inhibitors.
We have recently shown that (R)-N-(1-(2,4-dichlorophenyl)-
2-(1H-imidazol-1-yl)ethyl)-4-(5-phenyl-1,3,4-oxadiazol-2-yl)benz-
amide (VNI), the novel, non-toxic and highly potent experimental
inhibitor of T. cruzi CYP51, can efﬁciency cure both the acute and
chronic models of Chagas disease in mice infected with the Tulah-
uen strain of T. cruzi [11]. However, T. cruzi is a highly heteroge-
neous population, known to represent a pool of >70 different
Table 1
Sequence variations in CYP51s from different T. cruzi strains.a
T. cruzi strain CYP51 (GenBank Protein ID) Amino acids DNA
% identity # of differences (amino acid substitutions) % identity # of differences
CL-Brener A (XP_820210) 100 0 (none) >99 2 (2 silent)
B (XP_821219) 99 4 (G9A, D62E, A117S, E160K) 97 35 (31 silent)
Y A (AFW98339) 99 1 (P355S) >99 3 (2 silent)
B (AFW98340) 99 4 (G9A, D62E, A117S, E160K) 97 33 (29 silent)
Colombiana A (AGF25233) 98 8 (A117S, E160K, H196R, K203Q, V245I, K314E, D405E, P480S) 98 19 (11 silent)
B (AGF25234) 98 7 (G9A; L13P, P32S, D62E, A117S, E160K A288S) 97 39 (32 silent)
Sylvio Single, A-like (EKG07251) 98 6 (G9C, A117S, E160K, H196R, V245I, D405E)
Marinkellei Single, B-like (EKF39305) 95 24
The Y strain CYP51 accession numbers and the mutation that was studied in this work are in bold.
a Compared with Tulahuen CYP51.
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Fig. 1. Amino acid differences between CYP51s from Tulahuen and Y strains of T. cruzi. (A) Mapping Y-CYP51A amino acid variations on the Tulahuen CYP51 structure [3k1o].
Distal view. The protein backbone is rainbow colored, from the N terminus (blue) to the C-terminus (red). The residues that are different in the Y strain CYP51s are shown as
white carbon sticks, the variations are labeled. (B) Enlarged view of the substrate binding cavity in the in the CYP51 co-structure with VNI [3gw9]. P355 (K/b1-4 turn) and its
surface of interaction with VNI are colored in pink. The C atoms of VNI are gray. The C atoms of the heme are yellow. The water molecules are displayed as red spheres. The
hydrogen bonds are indicated as red dashes. The I and K helices are outlined and marked.
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strains vary signiﬁcantly in the disease progression (the time of par-
asitemia onset/peak), the severity of the acute stage, chronic symp-
toms (cardiac versus gastrointestinal) and particularly in drug
sensitivity [12,13]. The results of VNI testing in the stringent
short-term treatment protocols of mice infection with the Y and
Colombiana strains of T. cruzi (medium and high resistance to ben-
znidazole, respectively) have been inconclusive. Although VNI sup-
pressed parasitemia and prevented from mortality, no complete
parasitological cure was achieved under these conditions based
on the RT-PCR analysis after immunosuppression [14]. Ampliﬁca-
tion of CYP51 from Colombiana revealed the presence of two genes,
encoding eight (gene A) and seven (gene B) amino acid differences
from Tulahuen CYP51 (A-like) (Table 1), though none of these resi-
dues is located within the enzyme substrate binding cavity [14]. In
this work, we analyzed CYP51 in the Y strain of T. cruzi (Table 1 and
Fig. 1A). Again, two CYP51 genes were identiﬁed. CYP51Awas of par-
ticular interest because it carries a sequence variation that results in
the substitution of a highly conserved across the whole CYP51 fam-
ily proline residue (P355 in the T. cruzi CYP51 sequence numbering).
In the CYP51-VNI co-structure, this proline forms the surface of
interaction with the VNI carboxamide fragment (Fig. 1B). Replace-
ment of this proline with serine (the variation also found in theCYP51A paralogues from some intrinsically drug resistant ﬁlamen-
tous fungi, such as multiple species of Aspergillus (Fig. 2)), was likely
to increase ﬂexibility of this portion of the CYP51 binding cavity
therefore suggesting that its sensitivity to inhibition may be altered.
The ﬁndings of this work support this idea, imply that it might be
more preferable for CYP51 inhibitors aimed at serving as antichaga-
sic drug candidates to have a broad-spectrum activity rather than a
high target-selectivity, and outline a promising direction for the
CYP51 structure-based VNI scaffold development.
2. Materials and methods
2.1. T. Cruzi and mammalian cell cultures
Epithelial cells (Vero cell line) and cardiomyoblasts (H9C2 line)
were grown in Dulbecco’s modiﬁed Eagle’s medium (DMEM) sup-
plemented with 10% fetal bovine serum (FBS) and antibiotics at
37 C in an atmosphere of 5% CO2. Y strain T. cruzi epimastigotes
expressing green ﬂuorescent protein (GFP) (Y-GFP) (kindly pro-
vided by Dr. S. Schenkman, Universidade Federal de Sao Paulo
(Sao Paulo, Brazil)) were maintained in Diamond medium (0.1 M
NaCl, 0.05 M K2HPO4 pH 7.2, 0.625% tryptose, 0.625% tryptone,
0.625% yeast extract, 12.5 lg/mL Hemin) supplemented with 10%
Fig. 2. A fragment of multiple sequence alignment of CYP51 from different
biological kingdoms in the region of P355 (T. cruzi numbering). P355 is marked
with black arrow. P/S variation is also found in CYP51A in several ﬁlamentous
ascomycetes, whose constitutively expressed CYP51B paralogues always have P in
this position. More extended alignment can be seen as Supplemental Fig. 1.
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astigotes were obtained by in vitro metacyclogenesis of epimastig-
otes as described [15] and maintained in culture of Vero cells in
DMEM supplemented with 3% fetal bovine serum (FBS) and antibi-
otics at 37 C in an atmosphere of 5% CO2.
2.2. T. Cruzi cellular infection assays. Human stage (amastigotes)
The assay was perform using the conditions previously
described for testing antiparasitic activity of VNI in the Tulahuen
strain of T. cruzi [11]. Brieﬂy, Y-GFP trypomastigotes were usedDMSO
H
9C 2
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DMSO
Fig. 3. Antiparasitic effect of VNI in cardiomyoblasts and Vero cells infected with the Y st
multiplying within the host cells 72 h after treatment with different concentrations of V
blue, and actin myoﬁbrils are red.to infect Vero cells or cardiomyoblasts (10 parasites per cell) for
24 h. Unbound trypomastigotes were removed by washing with
DMEM. Infected mammalian cells were incubated with VNI or
(R)-N-(1-(3,40-diﬂuorobiphenyl-4-yl)-2-(1H-imidazol-1-yl)ethyl)-
4-(5-phenyl-1,3,4-oxadiazol-2-yl)benzamide (VFV) dissolved in
DMSO/DMEM in triplicate and co-cultured in DMEM + 3% FBS for
48 h to observe parasite multiplication. 72 h post-infection, the
cells were washed with phosphate-buffered saline, ﬁxed with
10% paraformaldehyde and stained with Hoechst to visualize
DNA and with TRITC phalloidin (Invitrogen) to visualize cardiomy-
ocyte or Vero actin myoﬁbrils. The number of parasites in each cell
was quantiﬁed by confocal microscopy using a FV1000 Confocal
Olympus microscope. Insect stage (epimastigotes). 1  106 epim-
astigotes of Y-GFP were cultured in Diamond medium in the pres-
ence of 1 lM VNI; VFV, or 1% DMSO (Control). Each 48 h the
medium was replaced by fresh medium at the same conditions.
Aliquots were collected every 24 h, and were mixed with 2% p-
formaldehyde in PBS (dilution 1:10). The parasites were counted
in Neubauer hemocytometer. The number of dead parasites was
determined by the dye exclusion method (0.1% of eosin in PBS).
2.3. CYP51 gene sequencing
Total DNA was isolated from Y strain T. cruzi epimastigotes as
described [16]. The CYP51 gene was then PCR ampliﬁed using a
FailSafe PCR Premix Selection Kit (Epicentre). The upstream
primer 50- CGCCATATGTTCATTGAAGCCATTGTATTGG-30 contained
a unique Nde I cloning site (underlined) and was complimentary
to the Tulahuen T. cruzi CYP51 cDNA (GenBank accession number
AY856083 [17] from 1 to 25 bp. The downstream primer
50-CGCAAGCTTCAGTGATGGTGATGCGAGGGCAATTTCTTCTTGCG-30
included a unique Hind III cloning site (underlined) followed by a
stop codon (bold) and C-terminal 4-histidine tag (italics), and
was complementary to the Tulahuen T. cruzi CYP51 sequence from
1443 to 1423 bp. Ampliﬁcation was carried out as described previ-
ously [17]. The PCR products were subcloned into pGEM-T Easy
vector (Promega) and sequenced. The Y-CYP51A and Y-CYP51B
cDNA and protein sequences were deposited into the NCBI
GenBank (http://www.ncbi.nih.gov/Genbank), nucleotide accession
numbers JQ434483 and JQ434484, respectively.500 nM 1 µM
5 nM 1 µM
rain of T. cruzi. Fluorescence microscopic observation of GFP-expressing amastigotes
NI versus control (DMSO). T. cruzi amastigotes are green, H9C2/Vero cells nuclei are
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Fig. 4. Spectral characteristics of Y-CYP51A. (A) Absolute absorbance spectrum (270–700 nm; spectrophotometric index A417/A280 = 1.42; DA(390–460)/DA(417–460) = 0.41) and
difference reduced carbon monoxide binding spectrum (400–500 nm). [P450] = 2.19 lM. (B) Type 1 spectral response to the binding of eburicol. [P450] = 1.6 lM. Upper:
absolute absorbance spectra, the Soret band maximum shifts to the left. Lower: difference spectra upon titration; titration step 0.5 lM; titration range 0.5–5.0 lM. Optical
path length 1 cm.
Table 2
Substrate binding, catalytic activity and inhibition of Y-CYP51A comparatively to Tulahuen CYP51.
CYP51 ortholog Substrate binding parameters Turnover number
(nmol substrate/
nmol P450/min)
Inhibition at I/E/S molar ratio1:1:100,
one hour reaction (%)
Kd, (lM) DA (% low-to-high
spin transition)
Binding efﬁciency
(DA/Kd) VNI VNT VFV
Tulahuen 0.8 36 45 5.6 ± 0.3 100 100 100
Y-CYP51A 1.54 48 31 2.0 ± 0.2 51 ± 2 35 ± 3 99 ± 0.8
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Fig. 5. Catalytic activity of Y-CYP51A in comparison with Tulahuen CYP51, time-
course. [P450] = 0.5 lM; [eburicol] = 50 lM.
T.S. Cherkesova et al. / FEBS Letters 588 (2014) 3878–3885 38812.4. Protein expression, puriﬁcation and spectral characterization
To obtain the expression construct, the Y-CYP51A gene insert
was subcloned into pCW as described [17]. The protein was coex-
pressed with GroEL/ES in E. coli DH5a and puriﬁed using metal
afﬁnity chromatography on Ni-NTA Agarose followed by anion-
exchange chromatography (CM-Sepharose). The absorption spec-
tra were recorded on a dual-beam Shimadzu UV-240IPC spectro-
photometer. P450 concentration was determined from the
absolute absorbance (e417 = 117 mm1 cm1) and reduced CO dif-ference spectra (De450–490 = 91 mm1 cm1). Substrate binding
parameters were calculated from the difference type I spectral
response (low-to-high spin transition of the P450 heme iron) at
the conditions described for Tulahuen T. cruzi CYP51 [17]. Binding
of VNI and its derivatives (R)-N-(1-(2,4-dichlorophenyl)-2-(1H-
1,2,4-triazol-1-yl)ethyl)-4-(5-phenyl-1,3,4-oxadiazol-2-yl)benzamide
(VNT) and VFV was monitored as type 2 spectral response reﬂect-
ing coordination of the P450 heme iron to the azole nitrogen. The
apparent Kds were calculated in Prism (GraphPad Software) using
a quadratic function for tight binding ligands [18].
2.5. CYP51 activity assay
Enzymatic activities of Tulahuen CYP51 and Y-CYP51A were
reconstituted as described previously [17]. The reaction products
were analyzed using a reverse-phase HPLC system (Waters)
equipped with b-RAM detector (INUS Systems, Inc.). Potencies of
the compounds to inhibit CYP51 activity were compared as inhibi-
tion of the substrate conversion in a one hour enzymatic reaction
[18,19].
2.6. X-ray crystallography
Crystallographic analysis was performed using Tulahuen T. cruzi
CYP51 structure (PDB ID 3k10) [20]. CYP51 co-structures with VNI
[21], VNT and VFV were determined using the orthologous enzyme
from T. brucei (PDB codes 3gw9, 4g3j, and 4g7g, respectively),
because these complexes diffract at atomic resolution (<2.0 Å).
3. Results
While in the cells infected by Tulahuen T. cruzi VNI completely
eradicates the parasite at 8 nM concentration (EC50 = 1.3 nM) [11],
in the Y strain infection its EC50 was found to be >5 nM, some trace
of amastigotes being observed within cardiomyoblasts and Vero
m
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Fig. 6. HPLC proﬁles of eburicol 14a-demethylation by Tulahuen CYP51 and Y-CYP51A. 1 h reaction; molar ratio enzyme: inhibitor substrate = 1:1:100. Triazole posaconazole
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ﬁcation of CYP51 from the Y strain DNA has shown that the effect of
VNI may possibly be weakened by the presence of two CYP51 genes
(higher CYP51 protein abundance, although it remains to be stud-
ied whether Y T. cruzi expresses both CYP51 paralogues constitu-
tively, or in both replicative stages of the life cycle). The former
can potentially be tested in the CL strain of T. cruzi, which also car-
ries two CYP51 genes (Table 1), CL-CYP51B being 100% identical to
Y-CYP51B, and CL-CYP51A (100% identical to Tulahuen-CYP51)
having one amino acid difference: P355 vs. S355 in Y-CYP51A.
In the CYP51 molecule P355 forms the surface of the active site
cavity (cytochrome P450 SRS5 [22]). Its substitution with serine in
Y-CYP51A was likely to increase the local ﬂexibility in the region.
Because it is our belief that high rigidity of the binding cavity pro-
vides the structural basis for CYP51 druggability and catalytic con-
servation [23], a more detailed analysis of Y-CYP51A was chosen as
the subject for this study.
The puriﬁed protein did not display any differences from Tulah-
uen-CYP51 in its absolute absorbance or CO-binding spectra
(Fig. 4A). Titration with the substrate produced a characteristic
type 1 spectral response (Fig. 4B); though both the Kd and the
amplitude of the low-to-high spin transition in the heme iron were
slightly higher (Table 2). Their ratio (DA/Kd) indicated lower appar-
ent binding efﬁciency, meaning that the Y-CYP51A ability to hold
the substrate molecule tightly during the three catalytic steps of
its 14a-demethylation [24] might be mildly affected. Lower bind-
ing efﬁciency correlated well with the about 3-fold slower catalytic
turnover (Fig. 5 and Table 2). Regardless of its lower enzymatic
activity, in the presence of equimolar amounts of VNI or its triazole
derivative VNT Y-CYP51A retained the ability to metabolize eburi-
col (26% and 40% conversion per hour, respectively), while Tulahu-
en CYP51 was completely inhibited at these conditions (Fig. 6 and
Table 2). In fact, among all tested inhibitors that are known to behighly potent against Tulahuen CYP51 [18,20,25], only VFV main-
tained essentially the same strength against both CYP51 orthologs.
The apparent binding efﬁciencies for VNI, VFV and VNT, calculated
from the Y-CYP51A titration curves (9, 87 and 2, respectively,
Fig. 7), are in good agreement with their inhibitory effects on the
enzymatic activity. Cellular experiments in insect and human
stages of Y T. cruzi also reﬂected higher antiparasitic potency of
VFV (Fig. 8). Collaborative studies on comparative testing of VNI
and VFV in animal models of Chagas infection with the Y strain
T. cruzi are currently underway and strongly support this observa-
tion (the results will be reported elsewhere).
4. Discussion
VNT and VFV (Fig. 9A) were designed with different purposes.
Lower basicity of the VNT triazole nitrogen weakens the Fe–N
coordination bond (Fig. 9B) therefore increasing the role of van
der Waals contacts and topological ﬁt between the inhibitor and
apoprotein [18] and leading to higher target selectivity. VNT was
proven to be as potent as VNI for Tulahuen T. cruzi CYP51, yet
has weaker inhibitory effect on the enzymes from T. brucei and L.
infantum [25]. The second aromatic ring of the VFV biphenyl frag-
ment was added to the molecule in order to ﬁll the deepest seg-
ment of the CYP51 binding cavity, which we believed should
broaden its spectrum of activity. The inhibitor was indeed con-
ﬁrmed as equally potent for all three tested protozoan CYP51s
[25]. P355S substitution in Y-CYP51A, ‘‘softening’’ the surface of
interaction around the inhibitor carboxamide fragment and its
hydrogen bond network with the enzyme I helix (Fig. 1), appears
to somewhat increase the impact of the Fe–N coordination bond
in the inhibitor-enzyme interaction. As a result VNI shows higher
potency than VNT, yet additional contacts with the protein pro-
vided by the distal ring of the biphenyl moiety of VFV (Fig. 9C)
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[P450] = 0.4 lM. Optical path length 5 cm. Upper: absolute absorbance spectra, the
Soret band maximum shifts to the right. Lower: difference spectra upon titration
with the inhibitors; titration step 0.2 lM, titration range 0.1–1.3 lM. Compounds
were added to the sample cuvette from 0.2 mM stock solutions in DMSO. At each
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ig. 8. Comparative effects of VNI and VFV in Y strain epimastigotes (A) and
mastigotes (B). (A) 1  106 epimastigotes were cultured in the presence of 1 lM
NI, VFV or 1% DMSO (Ctr). Each 48 h medium was replaced by fresh medium at the
ame conditions. Parasites were counted each day in a Neubauer chamber. (B) H9C2
ells were infected with trypomastigotes (MOI = 10). After 24 h the medium was
eplaced by fresh medium containing VNI or VFV. After 48 h of incubation with the
ompounds the cells were ﬁxed and prepared for microscopic analysis.
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replace the inhibitor in the reconstituted enzymatic reaction.
CYP51 is a highly conserved housekeeping gene found in all bio-
logical kingdoms. It is constitutively expressed in all organisms
that produce endogenous sterols [26]. Animals have one CYP51
gene. Some ﬁlamentous ascomycetes (such as Aspegrillus, Fig. 2)
have two or even three CYP51 genes (Fusarium [27]). While gene
B is expressed constitutively, gene A was reported to be inducible,
over-expressed at the conditions when a faster sterol ﬂow is
required [27,28]. Multiple CYP51 genes are found in some plants
(e.g. rice, potato), though the reasons for that remain to be under-
stood. While across the kingdoms CYP51s have low sequence sim-
ilarity [26], the identity in closely related species is very high: e.g.,
CYP51s from human and chimpanzee have only three amino acidF
a
V
s
c
r
cdifferences, CYP51s from human and dog differ in 9 residues (Sup-
plemental Fig. 2). Leishmania and T. brucei species have only one
CYP51 gene. CYP51s from L. infantum and L. donovani (both patho-
gens cause visceral leishmaniasis) are identical. CYP51s from T.
brucei brucei (causes nagana in cattle) and T. brucei gambiense
(causes sleeping sickness in humans) have one amino acid differ-
ence [29].
Surprisingly high variability observed in CYP51s of T. cruzi
(Table 1 and 16 amino acid differences between Y-CYP51A and
Marinkellei CYP51 (Supplemental Fig. 3)) suggests that these
organisms are likely to represent different species rather than
strains (which in turn would logically explain the profound differ-
ences in the disease progression), and CYP51 can potentially serve
as one of genetic markers. Sequencing of CYP51 genes from multi-
ple T. cruzi organisms should be helpful in estimating the evolu-
tionary distances between them and might be used for their
more meaningful classiﬁcation.
Heterogeneity of T. cruzi population may explain both the con-
troversy of the outcomes from posaconazole clinical trials and the
striking differences in the potencies of pyridine derivatives UDO
and UDD (highly selective for Tulahuen T. cruzi CYP51 [18]),
recently observed upon their testing in various T. cruzi strains
[30]. Although more studies are needed for establishing to what
extent the genetic variability of T. cruzi correlates with response
to drugs, it appears that the design of CYP51 inhibitors aimed at
serving as antichagasic chemotherapies should be more successful
if directed toward their broader spectrum of action rather than in
pursuit of single-target selectivity. Ideally, new drugs should be
active against all circulating variety of the parasite.
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Fig. 9. CYP51 structure based VNI scaffold development. (A) Structural formulas of VNI and its derivatives VNT and VFV. (B) Superimposition of CYP51 complexes with VNT
(gray) and VFV (red). The length of the Fe-N coordination bond in each complex is marked respectively. (C). Slice through the binding cavity of CYP51 complexes with VNI
(cyan) and VFV (red); surface representation. Left: overall structure, distal view. The SRS5 area (the C-terminal portion of helix K-b strand 1–4) is depicted as red ribbon.
Right: enlarged view of the active site. The heme is shown as orange spheres.
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